Prescription digital therapeutics (PDTs) are explored in behavior-driven conditions, such as substance abuse disorders.
The Expansion of Prescription Digital Therapeutics in Health Care
Megan Coder, PharmD, MBA, leads a discussion surrounding the evolution of software applications in the clinical setting.
Utilization of PDTs provides an array of financial considerations in treatment decisions.
Implementing prescription digital therapeutics can increase effectiveness of treatment pathways.
Through the inclusion of prescription digital therapeutics in individualized treatment plans, payers and providers are able to provide optimal and cost-effective care.
Medical experts discuss the impact of health inequities on the optimization of prescription digital therapeutic usage.
Dr Coder drives a discussion surrounding barriers to prescription digital therapeutic utilization.
Key opinion leaders provide insights regarding reimbursement challenges associated with the implementation of prescription digital therapeutics.
The panel provides an overview of the benefits surrounding the Access to Prescription Digital Therapeutics Act of 2023.
In closing thoughts, the panel discusses the future of prescription digital therapeutics within clinical practice.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
2
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
3
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
4
DCIS Redefined: Circulating Tumor Cells Prove Early Dissemination and Challenge the 'Preinvasive' Label
5
